

Date: 04 December 2025
Our ref: K: FOI/Ref: 2025-3175
Email: NSS.DevServicesFOI@nhs.scot

Freedom of Information Reference: FOI-2025-3175 – Coagulation Factors

I refer to your freedom of information request that we received on 07 November 2025 requesting the following information.

I am writing to submit a Freedom of Information (FOI) request regarding the use of coagulation factor products, specifically Bypassing Agents (BPAs; NovoSeven, FEIBA, Cevenfacta, and Obizur) and Hemlibra, to treat haemophilia and related conditions at NHS National Services Scotland. Please provide data for the period July through September 2025, as outlined below.

Where feasible, please supply data split by month and patient group, and include the full tables for each section as per the attached example.

1. How many patients did you treat with Bypassing agents (BPA)/Hemlibra inhibitor in (July, August, and September 2025)?
 - A) With BPA/Hemlibra Inhibitor?
 - B) Please fill in the BPA/Hemlibra products utilized in July, August, and September 2025)?

July through September 2025 Volume (IU)/mg Total Patients
Prophylaxis On demand
Example: FEIBA 50,000 IU 1 0 0

Hem A Inhibitor Patients
Haem A Inhibitor Patients FEIBA
Cevenfacta
NovoSeven
Hemlibra

Haem B Inhibitor Patients FEIBA
Cevenfacta
NovoSeven
Obizur

AHA Patients
AHA Patients FEIBA
NovoSeven
Obizur
Cevenfacta
Hemlibra

Other Use
FVII deficient NovoSeven



Chair Keith Redpath
Chief Executive Mary Morgan

NHS National Services Scotland is the common name of the
Common Services Agency for the Scottish Health Service

**Glanzmann's NovoSeven
Postpartum Haemorrhage (PPH) NovoSeven
PPH Cevenfacta
Other NovoSeven
Other Cevenfacta**

2. **For Hemlibra-treated patients, please indicate the number of patients by age group and dosing frequency for Q3'25 (July–September 2025)?**
3. **How many minor and major surgeries did your BPA patients have in July, August, and September 2025)?**
4. **Have any BPA patients switched products between July 1st through September 2025? What were the reasons for the switches?**

**Indication Previous Medication Previous Regimen Current Medication Current Regimen
Severity of patient Reason**

Example:

**Haem B Inh. 1 NovoSeven On-demand Cevenfacta Prophyl 1x/week Severe Patient
requested to try out a new product to improve treatment**

We have now completed the search of our records and can provide you with the following information:

1. **How many patients did you treat with Bypassing agents (BPA)/Hemlibra inhibitor in (July, August, and September 2025)?**
 - a) **With BPA/Hemlibra Inhibitor?**

Under Section 17 of the Freedom of Information Scotland Act, 2002 (FOISA) an organisation does not have to provide that information if it does not hold it. NHS National Services Scotland (NSS) does not hold the data for the exact number of patients treated with bypassing agents (BPAs) /Hemlibra inhibitor.

What we can provide is Appendix 1 – Patient IDs. This shows the number of patient identification (ID) numbers linked to orders through the delivery service for BPAs/Hemlibra Inhibitor under NP30919 - Homecare Deliveries of Clotting Medicines. Please note: These numbers do not necessarily equal the number of individual patients treated, as some IDs may be duplicates, for example, one patient ID may in fact have multiple orders.

Under Section 38(1)(b) of the FOISA, NSS has redacted information where the number of patients is five or fewer. This redaction has been applied to prevent the potential identification of individuals, in accordance with the data protection principles outlined in the UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018. The decision is also consistent with the Caldicott Principles.



Chair
Chief Executive

Keith Redpath
Mary Morgan

*NHS National Services Scotland is the common name of the
Common Services Agency for the Scottish Health Service*

b) Please fill in the BPA/Hemlibra products utilized in July, August, and September 2025)

Under section 17 of FOISA, an organisation does not have to provide that information if it does not hold it. NSS does not hold this level of information and as such, are unable to fill in the table you have provided asking for breakdowns by indication.

What we can provide you with Appendix 2 – Usage of Medicines. This shows the volume of BPA/Hemlibra products that were delivered to patients under NP30919 - Homecare Deliveries of Clotting Medicines. Although the data NSS holds shows the volume of BPA/Hemlibra products delivered to patients, NSS cannot confirm that the products were utilised. We recommend contacting the individual Health Boards (HBs) using the details provided below to obtain further information.

Under Section 38(1)(b) of FOISA, NSS has redacted information relating to the usage of certain products, specifically NovoSeven, where the associated patient numbers are five or fewer. This decision has been made to prevent the potential identification of individuals, in accordance with the data protection principles set out in the UK GDPR and the Data Protection Act 2018. The redaction is also consistent with the Caldicott Principles.

2. For Hemlibra-treated patients, please indicate the number of patients by age group and dosing frequency for Q3'25 (July–September 2025)?

Under section 17 of FOISA, an organisation does not have to provide that information if it does not hold it. NSS does not hold information relating to the patients by age group and dosing frequency as NSS does not record this level of information. We recommend contacting the individual HBs using the details provided below to obtain further information.

3. How many minor and major surgeries did your BPA patients have in July, August, and September 2025)?

Under section 17 of FOISA, an organisation does not have to provide that information if it does not hold it. NSS does not hold information relating to the number of minor or major surgeries that BPA/Hemlibra patients have undergone as NSS does not record this level of information. We recommend contacting the individual HBs using the details provided below to obtain further information.

4. Have any BPA patients switched products between July 1st through September 2025? What were the reasons for the switches?

Under section 17 of FOISA, an organisation does not have to provide that information if it does not hold it. NSS does not hold information relating to whether BPA patients have switched products as NSS does not record this level of information. We recommend contacting the individual HBs using the details provided below to obtain further information:



Chair
Chief Executive

Keith Redpath
Mary Morgan

*NHS National Services Scotland is the common name of the
Common Services Agency for the Scottish Health Service*

- NHS Ayrshire & Arran - foi@aapct.scot.nhs.uk
- NHS Borders - foi.enquiries@borders.scot.nhs.uk
- NHS Dumfries & Galloway - dq.feedback2@nhs.scot
- NHS Fife - fife.foirequestfife@nhs.scot
- NHS Forth Valley - fv.freedomofinformation@nhs.scot
- NHS Grampian - gram.foi@nhs.scot
- NHS Greater Glasgow & Clyde - foi@ggc.scot.nhs.uk
- NHS Highland - nhsh.foirequestshighland@nhs.scot
- NHS Lanarkshire - foi@lanarkshire.scot.nhs.uk
- NHS Lothian - loth.freedomofinformation@nhs.scot
- NHS Orkney - ORK.FOIrequests@nhs.scot
- NHS Shetland - shet.foi@nhs.scot
- NHS Tayside - tay.foisa@nhs.scot
- NHS Western Isles - wi.infogov-wihb@nhs.scot
- NHS Golden Jubilee - FOI@gjnh.scot.nhs.uk
- Healthcare Improvement Scotland - His.foi@nhs.scot
- NHS Education for Scotland - nes.foi@nhs.scot
- NHS Golden Jubilee - FOI@nwtc.scot.nhs.uk
- NHS24 - FOI@nhs24.scot.nhs.uk
- Public Health Scotland - Phs.foi@phs.scot
- The Scottish Ambulance Service - sas.foi@nhs.scot
- The State Hospital - TSH.FOI-Mailbox@nhs.scot


I trust you will find the information of assistance and if you require any further information, please do not hesitate to contact me.

If you are unhappy with any aspect of how we have dealt with your request, you can make representations to us asking us to review the handling of your request. Please write to the Associate Director Governance and Board Services (Board Secretary) at the email address nss.foi@nhs.scot within 40 working days of the date of this correspondence.

If after a review you are still unhappy, you also have the right to apply to the Scottish Information Commissioner, who can be contacted at Kinburn Castle, St Andrews, Fife, KY16 9DS, or via their [online application form](#).

If you have any queries about this letter, please contact me at the above address.

Yours sincerely,



Chair
Chief Executive

Keith Redpath
Mary Morgan

*NHS National Services Scotland is the common name of the
Common Services Agency for the Scottish Health Service*